Scott Jenkins Process electrification is gaining interest as a solution to industrial CO 2 emissions, which account for 20% of total CO 2 emissions in the U.S. . Several technologies are ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United ...

Key Points Revenue (GAAP) reached $124.1 million, surpassing the $115.5 million GAAP estimate and rising 29.7% year-over-year. Non-GAAP earnings per share improved to ($0.24), beating expectations and ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...

On July 31, Russia’s Defense Ministry announced that its forces had taken control of the Ukrainian city of Chasiv Yar, near ...

Increasing CD11c+ microglial subsets in the spinal dorsal horn by intrathecal treatment of interleukin-4 alleviate pain hypersensitivity caused by nerve injury.